Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
We create value for patients now and into the future. We work in a way that is sustainable for the patients who need our solutions, for the communities where we operate and for society. Find out more in our Integrated Annual Report 2019 https://t.co/FwdZC
— UCB News (@ucb_news) 20.02.2020 -
Check out our 2019 financial results, showing strong growth and potential to create even more patient value in the years ahead. https://t.co/aFXol9UFFK https://t.co/CWhYMagH11
— UCB News (@ucb_news) 20.02.2020 -
We are pleased to attend the @AIESEC annual conference where we will share our positive partnership experience and discuss sustainability https://t.co/Z92f36PrNm https://t.co/mBNIHqhg62
— UCB News (@ucb_news) 11.02.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
